№ lp_1_2_18536
File format: docx Character count: 4083 File size: 95 KB
The document outlines criteria for the preferred drug list (PDL) concerning fibromyalgia treatments under the MO HealthNet Pharmacy Program.
Year: 2026
Region / City: Missouri
Theme: Fibromyalgia Treatment
Document Type: Medical Criteria Proposal
Author: MO HealthNet and Conduent
Target Audience: MO HealthNet participants, healthcare providers
Approval Date: January 20, 2026
Period of Validity: Not specified
Change Date: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Hydrotherapy in the Management of Fibromyalgia: Overview and Evidence
Year: 2026
Region: International
Subject: Fibromyalgia and Hydrotherapy
Document Type: Review Article
Institution: Medical Research Review
Author: Unspecified
Target Audience: Healthcare professionals and researchers
Scope: Clinical applications of hydrotherapy for chronic pain
Key Topics: Pain management, physical therapy, aquatic therapy, patient quality of life
Evidence Base: Scientific studies, case reports, and clinical observations
Implementation Considerations: Risks, accessibility, feasibility, and best practices
SmartPA Criteria Proposal Drug/Drug Class: NSAIDs PDL Edit
Year: 2026
Region / City: MO HealthNet
Theme: NSAIDs, Pharmacology, Health Policy
Document Type: Proposal
Institution: MO HealthNet, Conduent
Author: MO HealthNet and Conduent
Target Audience: Healthcare Providers, Policy Makers, MO HealthNet Participants
Period of Validity: Indefinite
Approval Date: January 20, 2026
Modification Date: None
SmartPA Criteria Proposal Drug/Drug Class: Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations PDL Edit
Year: 2026
Region / city: Missouri
Document Type: Proposal
Organization: MO HealthNet
Author: MO HealthNet, Conduent
Target Audience: MO HealthNet participants, healthcare providers
Period of validity: Ongoing
Approval Date: January 20, 2026
Revision Date: May 21, 2008
Criteria Status: Revision of Existing Criteria
SmartPA Criteria ProposalDrug/Drug Class: Hereditary Angioedema Agents PDL Edit
Year: 2026
Region / City: Missouri
Topic: Hereditary Angioedema Treatment
Document Type: Proposal
Institution: MO HealthNet
Author: MO HealthNet and Conduent
Target Audience: Health professionals and stakeholders in the MO HealthNet program
Effective Period: Starting from May 9, 2019
Approval Date: January 20, 2026
Modification Date: Not specified
Document Status: Revision of Existing Criteria
Context: A proposal outlining the preferred drug list and approval criteria for hereditary angioedema treatment agents within the MO HealthNet program.
SmartPA Criteria ProposalDrug/Drug Class: Antiretroviral Therapy (ART) PDL EditFirst Implementation Date: April 7, 2022Proposed Date: January 20, 2026Prepared For: MO HealthNetPrepared By: MO HealthNet and Conduent
Year: 2026
Region / City: United States
Topic: Antiretroviral Therapy (ART)
Document Type: Proposal
Institution: MO HealthNet
Author: MO HealthNet, Conduent
Target Audience: Healthcare professionals, policymakers, and health program administrators
Effective Period: 2026–
Approval Date: January 20, 2026
Revision Date: April 7, 2022
SmartPA Criteria Proposal Drug/Drug Class: NSAIDs PDL Edit
Year: 2026
Region / City: MO HealthNet
Theme: NSAIDs, Pharmacology, Health Policy
Document Type: Proposal
Institution: MO HealthNet, Conduent
Author: MO HealthNet and Conduent
Target Audience: Healthcare Providers, Policy Makers, MO HealthNet Participants
Period of Validity: Indefinite
Approval Date: January 20, 2026
Modification Date: None
SmartPA Criteria ProposalDrug/Drug Class: Neuropathic Pain Agents PDL Edit
Year: 2026
Region / City: Missouri, USA
Topic: Neuropathic Pain Agents
Document Type: Proposal
Institution: MO HealthNet
Author: MO HealthNet and Conduent
Target Audience: Healthcare providers and MO HealthNet participants
Approval Period: 1 year
Approval Date: January 20, 2026
Revision Date: May 29, 2013
SmartPA Criteria ProposalDrug/Drug Class: Anticonvulsants, Dravet Syndrome PDL Edit
Year: 2026
Region / City: MO HealthNet
Topic: Dravet Syndrome, Anticonvulsants
Document Type: Proposal
Organization: MO HealthNet
Author: MO HealthNet and Conduent
Target Audience: Healthcare providers, MO HealthNet participants
Effective Period: Ongoing
Approval Date: January 20, 2026
Amendment Date: N/A
SmartPA Criteria Proposal Drug/Drug Class: Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations PDL Edit
Year: 2026
Region / city: Missouri
Document Type: Proposal
Organization: MO HealthNet
Author: MO HealthNet, Conduent
Target Audience: MO HealthNet participants, healthcare providers
Period of validity: Ongoing
Approval Date: January 20, 2026
Revision Date: May 21, 2008
Criteria Status: Revision of Existing Criteria
Topics: Fibromyalgia DrugDrug SmartPA